News headlines about Novocure (NASDAQ:NVCR) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novocure earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 46.0256162121841 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern’s scoring:
- Quotidian Technical Highlights on Selected Medical Equipment Stocks — Accuray, K2M Group, NuVasive, and NovoCure – PR Newswire (press release) (prnewswire.com)
- Commit To Buy NovoCure At $15, Earn 14.8% Annualized Using Options (nasdaq.com)
- Insider Selling: Novocure Ltd (NVCR) CEO Sells 14,900 Shares of Stock (americanbankingnews.com)
- Novocure Ltd (NVCR) CEO Asaf Danziger Sold $7.5 million of Shares (finance.yahoo.com)
Shares of Novocure (NVCR) opened at $21.90 on Wednesday. Novocure has a twelve month low of $6.00 and a twelve month high of $22.90. The firm has a market capitalization of $1,960.00 and a PE ratio of -26.39. The company has a quick ratio of 5.30, a current ratio of 5.90 and a debt-to-equity ratio of 0.83.
Novocure (NASDAQ:NVCR) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.07. Novocure had a negative return on equity of 57.68% and a negative net margin of 47.45%. The company had revenue of $50.10 million during the quarter, compared to analyst estimates of $43.45 million. During the same quarter last year, the firm posted ($0.39) EPS. The firm’s revenue for the quarter was up 130.9% on a year-over-year basis. analysts forecast that Novocure will post -0.65 earnings per share for the current year.
A number of equities research analysts have recently commented on the company. BidaskClub upgraded Novocure from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Zacks Investment Research cut Novocure from a “buy” rating to a “hold” rating in a research note on Saturday, January 13th. ValuEngine upgraded Novocure from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Wedbush reiterated an “outperform” rating and set a $25.00 target price (down from $29.00) on shares of Novocure in a research note on Friday, October 27th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Novocure in a research note on Monday, November 20th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Novocure has a consensus rating of “Buy” and an average price target of $21.13.
In related news, CEO Asaf Danziger sold 15,866 shares of Novocure stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $22.01, for a total value of $349,210.66. Following the completion of the sale, the chief executive officer now owns 774,040 shares of the company’s stock, valued at approximately $17,036,620.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Michael J. Ambrogi sold 1,200 shares of Novocure stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $22.00, for a total value of $26,400.00. Following the transaction, the chief operating officer now directly owns 24,987 shares of the company’s stock, valued at approximately $549,714. The disclosure for this sale can be found here. In the last three months, insiders sold 662,921 shares of company stock valued at $14,318,774. 16.70% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Novocure (NVCR) Stock Price” was published by Stock Observer and is owned by of Stock Observer. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.thestockobserver.com/2018/01/24/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-novocure-nvcr-stock-price.html.
Novocure Company Profile
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.